

## Medical Policy Manual **Draft Revision Policy: Do Not Implement**

### Mogamulizumab-kpkc (Poteligeo®)

#### IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

**The proposal is to add text/statements in red and to delete text/statements with strikethrough:  
POLICY**

#### INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

Poteligeo is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

##### Compendial Uses

- Mycosis fungoides (MF) or Sézary syndrome (SS)
- Adult T-cell leukemia/lymphoma (ATLL)

All other indications are considered experimental/investigational and not medically necessary.

#### COVERAGE CRITERIA

##### **Mycosis Fungoides (MF) or Sézary Syndrome (SS)**

Authorization of 12 months may be granted for treatment of mycosis fungoides (MF) or Sézary syndrome (SS).

##### **Adult T-Cell Leukemia/Lymphoma (ATLL)**

Authorization of 12 months may be granted for treatment of ATLL when used **in one of the following ways:**

- As a single agent **when used as** subsequent therapy for chronic high risk, acute, or lymphoma subtypes.
- **In combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) if no intention to proceed to transplant.**

#### CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the Coverage Criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.



## Medical Policy Manual **Draft Revision Policy: Do Not Implement**

### **APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS**

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

### **ADDITIONAL INFORMATION**

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

### **REFERENCES**

1. Poteligeo [package insert]. Princeton, NJ: Kyowa Kirin, Inc.; **January 2025**.
2. The NCCN Drugs & Biologics Compendium® © **2025** National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org>. Accessed **December 15, 2025**.

### **EFFECTIVE DATE**

ID\_CHS\_2026